Stephens analyst Sudan Loganathan raised the firm’s price target on Kymera Therapeutics (KYMR) to $110 from $65 and keeps an Overweight rating on the shares after the company reported positive Phase 1b BroADen data in moderate-to-severe atopic dermatitis. The totality of evidence points to a “compelling” efficacy and safety profile that supports durability in subsequent AD and asthma trials, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics’ KT-621 in dermatitis granted Fast Track Designation by FDA
- Kymera Therapeutics price target raised to $120 from $81 at Mizuho
- Kymera Therapeutics Announces Major Stock Offering
- Kymera Therapeutics price target raised to $125 from $70 at JPMorgan
- Kymera Therapeutics 7M share Secondary priced at $86.00